Cat. No.: HY-50895

Gefitinib

(Synonyms: ZD1839)

206 Cited Publications

Customer Review

Based on 206 publication(s) in Google Scholar

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

For research use only. We do not sell to patients.

Purity: 99.99%
CAS No.: 184475-35-2
Formula: C₂₂H₂₄ClFN₄O₃
Molecular Weight:446.90

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Gefitinib Chemical Structure

CAS No.: 184475-35-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (206)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

EGFR

All EGFR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	12.71 μM Compound: gefitinib	Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
16HBE14o-	IC₅₀	1.601 μM Compound: Gefitinib	Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
16HBE14o-	IC₅₀	12.71 μM Compound: Iressa	Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay	[PMID: 24607591]
A-375	IC₅₀	20.55 μM Compound: Gefitinib	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	[PMID: 20304537]
A-431	IC₅₀	0.023 μM Compound: 29	In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay	[PMID: 11459659]
A-431	IC₅₀	0.276 μg/mL Compound: 1 iressa	Inhibition of A431 cell proliferation Inhibition of A431 cell proliferation	[PMID: 12270171]
A-431	ED₅₀	50 mg/kg Compound: Chemical probe : ZD1839	Antitumor activity against human A-431 cells xenografted in po dosed Swiss nu/nu mouse assessed as tumor growth inhibition administered on day 7 post implantation measured after 3 weeks Antitumor activity against human A-431 cells xenografted in po dosed Swiss nu/nu mouse assessed as tumor growth inhibition administered on day 7 post implantation measured after 3 weeks	[PMID: 12384534]
A-431	IC₅₀	12.05 μM Compound: 1	Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay	[PMID: 18771819]
A-431	GI₅₀	0.514 μM Compound: Ire	Growth inhibition of human A431 cells after 72 hrs by MTT assay Growth inhibition of human A431 cells after 72 hrs by MTT assay	[PMID: 19969465]
A-431	IC₅₀	2.15 μM Compound: Gfb	Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay	[PMID: 22339342]
A-431	IC₅₀	1.08 μM Compound: Gifitinib	Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay	[PMID: 22698782]
A-431	IC₅₀	1.41 μM Compound: Gifitinib	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22698782]
A-431	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
A-431	IC₅₀	4.485 μM Compound: gefitinib	Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A-431	IC₅₀	8.982 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
A-431	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA	[PMID: 24094432]
A-431	IC₅₀	1.98 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24094432]
A-431	IC₅₀	0.55 μM Compound: Gefitinib, Iressa	Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay	[PMID: 24411123]
A-431	IC₅₀	4.485 μM Compound: Iressa	Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A-431	IC₅₀	4 μM Compound: Gefitinib	Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
A-431	IC₅₀	4 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
A-431	IC₅₀	3.74 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 26706113]
A-431	IC₅₀	1.33 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A-431	IC₅₀	4.58 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay	[PMID: 27387355]
A-431	IC₅₀	0.55 μM Compound: Iressa	Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
A-431	IC₅₀	3.308 μM Compound: 1	Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay	[PMID: 27634676]
A-431	IC₅₀	33 nM Compound: 1	Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method	[PMID: 27769671]
A-431	IC₅₀	12.58 μM Compound: Gefitinib	Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay	[PMID: 28236592]
A-431	IC₅₀	6.12 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A-431	IC₅₀	3.3 μM Compound: 1; Iressa	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A-431	EC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
A-431	EC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
A-431	IC₅₀	768 nM Compound: Gefitinib	Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
A-431	IC₅₀	1.282 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay	[PMID: 30471829]
A-431	IC₅₀	2.47 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 30508379]
A-431	IC₅₀	4.45 μM Compound: ZD1839	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A-431	IC₅₀	2.6 μM Compound: 1	Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
A-431	IC₅₀	0.55 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
A-431	IC₅₀	2.98 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	3.308 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	31.2 μM Compound: IRESSA; ZD1839	Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay	[PMID: 33260051]
A-431	IC₅₀	8.37 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A-431	IC₅₀	16.02 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	24.55 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	32.17 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	1.89 μM Compound: Gefitinib	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
A498	IC₅₀	8.6 μM Compound: 1, Iressa	Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
A498	GI₅₀	0.4 μM Compound: Gefitinib	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A549	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring K-ras G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human A549 cells harboring K-ras G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
A549	IC₅₀	13.59 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 18313807]
A549	IC₅₀	7 μM Compound: gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method	[PMID: 19268405]
A549	IC₅₀	37.93 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
A549	IC₅₀	10.08 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
A549	IC₅₀	10.21 μM Compound: Gfb	Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay	[PMID: 22339342]
A549	IC₅₀	11.8 μM Compound: Gifitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22698782]
A549	IC₅₀	15.58 μM Compound: gefitinib	Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A549	IC₅₀	4.626 μM Compound: Gefitinib	Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay	[PMID: 23792318]
A549	IC₅₀	20.3 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
A549	IC₅₀	39.9 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	498 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	12.92 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24094432]
A549	IC₅₀	15.58 μM Compound: Iressa	Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A549	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
A549	IC₅₀	11.67 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	12.17 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	0.13 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay	[PMID: 26003342]
A549	IC₅₀	8.4 μM Compound: gefitinib	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 26192023]
A549	IC₅₀	11.02 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay	[PMID: 26451770]
A549	IC₅₀	8.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 26560049]
A549	IC₅₀	5.76 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26706113]
A549	IC₅₀	39.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A549	IC₅₀	9.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
A549	IC₅₀	24.25 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27132165]
A549	IC₅₀	13.32 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A549	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
A549	GI₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
A549	IC₅₀	29.43 μM Compound: 1	Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay	[PMID: 27634676]
A549	IC₅₀	5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay	[PMID: 28236592]
A549	GI₅₀	9.3 μM Compound: Gefitinib	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 28291344]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay	[PMID: 28366268]
A549	IC₅₀	36.21 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A549	IC₅₀	10.07 μM Compound: 1; Iressa	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A549	IC₅₀	22.5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28462838]
A549	IC₅₀	12.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28711702]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay	[PMID: 28711703]
A549	EC₅₀	18.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A549	IC₅₀	21.9 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28927795]
A549	IC₅₀	8.27 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 29407971]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay	[PMID: 29421573]
A549	IC₅₀	10.45 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
A549	IC₅₀	1260 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29576272]
A549	IC₅₀	10.07 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30471829]
A549	IC₅₀	60 nM Compound: 1	Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis	[PMID: 30472599]
A549	IC₅₀	2.96 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30503938]
A549	IC₅₀	11.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30508379]
A549	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
A549	IC₅₀	5.74 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30655941]
A549	IC₅₀	17.9 μM Compound: Iressa(TM)	Antiproliferative activity against human A549 after 18 hrs by MTT assay Antiproliferative activity against human A549 after 18 hrs by MTT assay	[PMID: 30826188]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
A549	IC₅₀	21.17 μM Compound: ZD1839	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A549	IC₅₀	2.11 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
A549	IC₅₀	20 μM Compound: Gefitinib	Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
A549	IC₅₀	14.803 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
A549	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
A549	IC₅₀	10.5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell death Antiproliferative activity against human A549 cells assessed as cell death	[PMID: 32035700]
A549	IC₅₀	15.79 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 5 days by SRB assay Growth inhibition of human A549 cells incubated for 5 days by SRB assay	[PMID: 32145644]
A549	IC₅₀	0.007 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
A549	IC₅₀	2.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.65 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	15.59 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A549	IC₅₀	3.53 μM Compound: Gefitinib	Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
A549	IC₅₀	2.69 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
A549	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 34922028]
A549	IC₅₀	13.26 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay	[PMID: 35247755]
A549	IC₅₀	>50 μM Compound: Gefitinib	Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
A549	IC₅₀	11.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
A549	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	14.5 μM Compound: Gefitinib	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37952262]
A549	IC₅₀	5.44 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
A549	IC₅₀	6.249 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
A549	IC₅₀	5.44 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 38665827]
A549	IC₅₀	8.51 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
ASPC1	IC₅₀	6.73 μM Compound: Gefitinib	Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay	[PMID: 30471829]
B16-F10	IC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 25866240]
B16-F10	ED₅₀	0.91 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	2.7 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	26 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	3.1 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR A767_V769duspASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR A767_V769duspASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	306 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	35 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	4.1 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	4.8 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	7.4 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	8.3 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	10.8 nM Compound: gefitinib	Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant	[PMID: 19239229]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR A767_V769dupASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR A767_V769dupASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M double mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M double mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	1.9 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins G776V,C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins G776V,C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	2.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins 774YVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins 774YVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	3 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	454 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	760 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring wildtype ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring wildtype ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>10000 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells expressing IL-3 assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Cytotoxicity against mouse BaF3 cells expressing IL-3 assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
BaF3	IC₅₀	10.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	12.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	1757 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	21.8 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	2779.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	53.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	54.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	6981.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	2500 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BaF3	IC₅₀	55.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BaF3	IC₅₀	19.96 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR D770_N771insSVD by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring EGFR D770_N771insSVD by CellTiter-Glo assay	[PMID: 38518121]
BEAS-2B	IC₅₀	13.94 μM Compound: gefitinib	Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
BEAS-2B	IC₅₀	13.94 μM Compound: Iressa	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 24607591]
Bel-7402	IC₅₀	11.21 μM Compound: Gef	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
BT-474	EC₅₀	300 nM Compound: Iressa	Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining	[PMID: 19028424]
BT-474	IC₅₀	0.36 μM Compound: Gefitinib, Iressa	Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
BT-474	IC₅₀	0.53 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay	[PMID: 27132165]
BT-474	IC₅₀	1.24 μM Compound: Gefitinib	Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
BT-474	IC₅₀	0.36 μM Compound: Iressa	Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
BT-474	IC₅₀	0.365 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
BT-549	IC₅₀	6.56 μM Compound: Gefitinib	Cytotoxicity against human BT549 cells after 72 hrs by SRB assay Cytotoxicity against human BT549 cells after 72 hrs by SRB assay	[PMID: 29407971]
BT-549	IC₅₀	6.76 μM Compound: Gefitinib	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
Calu-3	IC₅₀	1.4 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells overexpressing ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Calu-3 cells overexpressing ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
Calu-3	IC₅₀	2.7 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells harboring ERBB2 amp mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Calu-3 cells harboring ERBB2 amp mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
Calu-3	IC₅₀	1.6 μM Compound: Gefitinib	Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
Calu-3	IC₅₀	0.99 μM Compound: Gefitinib, Iressa	Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
Calu-3	IC₅₀	0.985 μM Compound: Gefitinib	Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
Calu-3	IC₅₀	4.52 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells by CCK8 assay Antiproliferative activity against human Calu-3 cells by CCK8 assay	[PMID: 34922028]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
CHO-K1	GI₅₀	43.7 μM Compound: Gefitinib	Growth inhibition of CHOK1 cells after 48 hrs by MTT assay Growth inhibition of CHOK1 cells after 48 hrs by MTT assay	[PMID: 28291344]
CL97	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
CNE	IC₅₀	23.5 μM Compound: Gefitinib	Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
CWR22R	IC₅₀	14 μM Compound: Gefitinib	Growth inhibition of human 22Rv1 cells after 5 days by SRB assay Growth inhibition of human 22Rv1 cells after 5 days by SRB assay	[PMID: 32484346]
DU-145	IC₅₀	42.17 μM Compound: Gefitinib	Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
DU-145	IC₅₀	>100 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 23871909]
DU-145	IC₅₀	8.63 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 28711702]
DU-145	IC₅₀	>100 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
DU-145	IC₅₀	7.3 μM Compound: Gefitinib	Growth inhibition of human DU145 cells after 5 days by SRB assay Growth inhibition of human DU145 cells after 5 days by SRB assay	[PMID: 32484346]
ECa-109 cell line	IC₅₀	26.47 μM Compound: Gefitinib	Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
FaDu	IC₅₀	0.05 μM Compound: Gefitinib	Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
H322	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human H322 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human H322 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC4006	IC₅₀	0.05 μM Compound: Gefitinib	Antiproliferative activity against human HCC4006 cells harboring EGFR Del L747_E749 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC4006 cells harboring EGFR Del L747_E749 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.004 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.008 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.008 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.026 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.927 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	1.93 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	4.82 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 Ins 774YVMA assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 Ins 774YVMA assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	8 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
HCC827	IC₅₀	12 nM Compound: gefitinib	Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay	[PMID: 20550212]
HCC827	IC₅₀	0.013 μM Compound: 1, ZD-1839	Antiproliferative activity against human HCC827 cells by MTS assay Antiproliferative activity against human HCC827 cells by MTS assay	[PMID: 20961149]
HCC827	IC₅₀	0.008 μM Compound: Gfb	Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay	[PMID: 22339342]
HCC827	IC₅₀	0.0015 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCC827	IC₅₀	0.006 μM Compound: gefitinib	Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay	[PMID: 23792318]
HCC827	IC₅₀	0.012 μM Compound: 1	Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
HCC827	IC₅₀	5.81 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay	[PMID: 24053674]
HCC827	IC₅₀	0.006 μM Compound: Iressa	Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay	[PMID: 24607591]
HCC827	IC₅₀	33 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay	[PMID: 25937236]
HCC827	IC₅₀	0.013 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
HCC827	IC₅₀	0.002 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay	[PMID: 28236592]
HCC827	IC₅₀	0.0099 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
HCC827	IC₅₀	0.006 μM Compound: 1; Iressa	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
HCC827	EC₅₀	<0.014 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
HCC827	IC₅₀	1.6 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay	[PMID: 29421573]
HCC827	IC₅₀	33.3 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 29576272]
HCC827	IC₅₀	0.16 x 10^-2 μM Compound: ZD1839	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
HCC827	CC₅₀	26 nM Compound: Gefitinib	Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
HCC827	IC₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
HCC827	IC₅₀	0.00169 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
HCC827	IC₅₀	64 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR del19 mutant assessed as inhibition of cell growth Antiproliferative activity against human HCC827 cells expressing EGFR del19 mutant assessed as inhibition of cell growth	[PMID: 35728507]
HCC827	IC₅₀	9.08 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
HCC827	IC₅₀	7.3 nM Compound: 1	Antiproliferative activity against human HCC827 cells harboring EGFR del E746_A750 mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746_A750 mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37934858]
HCC827	IC₅₀	0.23 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells by CellTiter-Glo assay Antiproliferative activity against human HCC827 cells by CellTiter-Glo assay	[PMID: 38518121]
HCC827	IC₅₀	0.019 μM Compound: 1	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
HCC827	IC₅₀	0.041 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
HCT-116	IC₅₀	66.9 μM Compound: GF	Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HCT-116	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCT-116	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HCT-116	IC₅₀	5.98 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 29407971]
HCT-116	IC₅₀	21.55 μM Compound: Iressa(TM)	Antiproliferative activity against human HCT116 after 18 hrs by MTT assay Antiproliferative activity against human HCT116 after 18 hrs by MTT assay	[PMID: 30826188]
HCT-116	IC₅₀	19.82 μM Compound: Gefitinib	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
HCT-116	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	6.46 μM Compound: Gefitinib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
HCT-15	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HEK293	IC₅₀	420 nM Compound: Gefitinib	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HEK-293T	CC₅₀	52.03 μM Compound: Gefitinib	Cytotoxicity against human 293T cells after 24 hrs by MTT assay Cytotoxicity against human 293T cells after 24 hrs by MTT assay	[PMID: 25866240]
HEK-293T	IC₅₀	84.87 μM Compound: Gefitinib	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
HeLa	IC₅₀	45.59 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20304537]
HeLa	IC₅₀	108.3 μM Compound: GF	Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HeLa	IC₅₀	2.67 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HeLa	IC₅₀	2.26 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	15.4 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HeLa	GI₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
HeLa	IC₅₀	18.3 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28462838]
HeLa	IC₅₀	9.68 μM Compound: Gefitinib	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	4.3 μM Compound: Gefitinib	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
HeLa	IC₅₀	1.48 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30342958]
HeLa	IC₅₀	23.92 μM Compound: Gefitinib	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HeLa	IC₅₀	39.32 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 34922028]
HEp-2	CC₅₀	>100 μM Compound: 24	Cytotoxicity against human HEp-2 cells Cytotoxicity against human HEp-2 cells	[PMID: 33539089]
HepG2	IC₅₀	6.42 μM Compound: Iressa	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22727449]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HepG2	IC₅₀	29.79 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23871909]
HepG2	IC₅₀	6.42 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HepG2	IC₅₀	0.12 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay	[PMID: 26003342]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
HepG2	IC₅₀	18.22 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 26560049]
HepG2	IC₅₀	7.52 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
HepG2	IC₅₀	>50 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
HepG2	IC₅₀	15.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28462838]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28711702]
HepG2	IC₅₀	18.36 μM Compound: Iressa(TM)	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30826188]
HepG2	IC₅₀	6.6 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
HepG2	IC₅₀	33.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
HepG2	IC₅₀	24.19 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
HepG2	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	16.1 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38784474]
HGC-27	IC₅₀	12.44 μM Compound: Gefitinib	Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
HL-60	IC₅₀	54.5 μM Compound: Gifitinib	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22698782]
HN5	EC₅₀	10 nM Compound: Iressa	Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining	[PMID: 19028424]
HOP-62	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HOP-92	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Hs-578T	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Hs-578T	IC₅₀	17.22 μM Compound: Gefitinib	Cytotoxicity against human Hs-578T cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Hs-578T cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
HT-29	IC₅₀	9.8 μM Compound: Iressa	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20056425]
HT-29	IC₅₀	16.93 μM Compound: Gefitinib	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20304537]
HT-29	IC₅₀	3.36 μM Compound: Iressa	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22727449]
HT-29	IC₅₀	110.3 μM Compound: GF	Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HT-29	IC₅₀	3.63 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	5.21 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	3.63 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	5.21 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26451770]
HT-29	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay	[PMID: 28366268]
Huh-7	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
Huh-7	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human Huh-7 cells Antiproliferative activity against human Huh-7 cells	[PMID: 33421712]
HuTu80	ED₅₀	0.77 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
HUVEC	IC₅₀	0.03 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against EGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against EGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	IC₅₀	1 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against FGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against FGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	IC₅₀	1 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against VEGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against VEGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	GI₅₀	13 μM Compound: Gefitinib	Growth inhibition of HUVEC after 48 hrs by MTT assay Growth inhibition of HUVEC after 48 hrs by MTT assay	[PMID: 28291344]
IGROV-1	GI₅₀	0.2 μM Compound: Gefitinib	Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	9.36 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human K562 cells after 96 hrs by MTT assay Cytotoxicity against human K562 cells after 96 hrs by MTT assay	[PMID: 18313807]
K562	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
K562	GI₅₀	2.51 μM Compound: Gefitinib	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	14.27 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 35247755]
K562/A02	IC₅₀	32.35 μM Compound: Gefitinib	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 35247755]
KB	IC₅₀	0.054 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against EGF stimulated human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against EGF stimulated human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
KB	IC₅₀	8.8 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
KB	IC₅₀	0.054 μM Compound: Iressa	Antiproliferative activity against EGF-stimulated human KB cell line Antiproliferative activity against EGF-stimulated human KB cell line	[PMID: 16516473]
KB	IC₅₀	80 nM Compound: 1	Antiproliferative activity against EGF-stimulated KB cells Antiproliferative activity against EGF-stimulated KB cells	[PMID: 16806916]
KB	IC₅₀	2.8 μM Compound: 1, Iressa	Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
KB	IC₅₀	0.025 μM Compound: Gefitinib, Iressa	Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA	[PMID: 24411123]
KB	IC₅₀	0.025 μM Compound: Gefitinib	Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA	[PMID: 32139324]
KB	IC₅₀	54 nM Compound: 1	Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33540357]
KB	ED₅₀	0.33 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
KB 3-1	IC₅₀	0.08 μM Compound: 29	In vitro inhibitory activity against EGF-stimulated proliferation of KB2 cells in culture In vitro inhibitory activity against EGF-stimulated proliferation of KB2 cells in culture	[PMID: 11459659]
KM12	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
L02	IC₅₀	>10 μM Compound: Gfb	Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay	[PMID: 22339342]
L02	IC₅₀	19.8 μM Compound: Gefitinib	Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
L02	IC₅₀	7.14 μM Compound: Gefitinib	Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
L02	IC₅₀	13.26 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
L02	IC₅₀	33.17 μM Compound: Gefitinib	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
L02	IC₅₀	10.08 μM Compound: 4	Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay	[PMID: 34216747]
L02	IC₅₀	45.31 μM Compound: Gefitinib	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 34922028]
L02	IC₅₀	55.08 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay	10.1039/C2MD20078C
L132	ED₅₀	>1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
L929	IC₅₀	1.98 μM Compound: Gefitinib	Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 30508379]
LoVo	IC₅₀	0.062 μM Compound: 1	Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay	[PMID: 23930994]
LoVo	IC₅₀	59 nM Compound: 10	Growth inhibition of human LoVo cells harboring wild type EGFR Growth inhibition of human LoVo cells harboring wild type EGFR	[PMID: 32432477]
LOX IMVI	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Macrophage	CC₅₀	280.6 μM Compound: Gefitinib	Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay	[PMID: 24731281]
MCF-10A	IC₅₀	30 μM Compound: Gefitinib	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF-10A	IC₅₀	20.54 μM Compound: Gefitinib	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MCF7	IC₅₀	1 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 18771819]
MCF7	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MCF7	IC₅₀	69.16 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20304537]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
MCF7	EC₅₀	>50 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay	[PMID: 25198997]
MCF7	EC₅₀	35 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF7	IC₅₀	10.29 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25866240]
MCF7	IC₅₀	3.3 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MCF7	IC₅₀	17.83 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
MCF7	IC₅₀	13.1 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
MCF7	IC₅₀	25.37 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27132165]
MCF7	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MCF7	GI₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
MCF7	GI₅₀	20.8 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28711702]
MCF7	IC₅₀	26.7 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29407971]
MCF7	IC₅₀	6.77 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30342958]
MCF7	GI₅₀	>30 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 30447889]
MCF7	IC₅₀	6.26 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30503938]
MCF7	IC₅₀	20.68 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 after 18 hrs by MTT assay Antiproliferative activity against human MCF7 after 18 hrs by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	23.52 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 by MTT assay Antiproliferative activity against human MCF7 by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	7.34 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MCF7	IC₅₀	2.97 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
MCF7	IC₅₀	>100 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
MCF7	IC₅₀	3.3 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 33421712]
MCF7	IC₅₀	3.57 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
MCF7	IC₅₀	13.24 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 34922028]
MCF7	IC₅₀	0.76 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MCF7	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	ED₅₀	0.89 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MDA-MB-231	IC₅₀	36.61 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 18313807]
MDA-MB-231	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
MDA-MB-231	EC₅₀	>50 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	EC₅₀	25 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	IC₅₀	4.1 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-231	IC₅₀	37.82 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27132165]
MDA-MB-231	GI₅₀	12.6 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-231	GI₅₀	14.2 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28291344]
MDA-MB-231	GI₅₀	15 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 28291344]
MDA-MB-231	IC₅₀	28.3 μM Compound: Gefitinib	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
MDA-MB-231	IC₅₀	8.72 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MDA-MB-231	IC₅₀	6.85 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	4.1 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 33421712]
MDA-MB-231	IC₅₀	7.12 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MDA-MB-231	IC₅₀	14.52 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 34922028]
MDA-MB-231	IC₅₀	4.68 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MDA-MB-231	IC₅₀	45.31 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
MDA-MB-468	IC₅₀	3.9 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-468	GI₅₀	0.01 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-468	GI₅₀	9.7 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MDA-MB-468	GI₅₀	25.5 μM Compound: Gefitinib	Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 30447889]
MDA-MB-468	IC₅₀	3.9 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 33421712]
MDA-MB-468	IC₅₀	2.51 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MDCK	IC₅₀	1.26 μM Compound: Gefitinib	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
MDCK	GI₅₀	1.45 μM Compound: Gefitinib, Iressa	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24184213]
MDCK-II	IC₅₀	3.19 μM Compound: Gefitinib, Iressa	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay	[PMID: 24184213]
MDCK-II	GI₅₀	1.36 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay	[PMID: 30390439]
MDCK-II	GI₅₀	2.1 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells after 72 hrs by MTT assay Growth inhibition of MDCK2 cells after 72 hrs by MTT assay	[PMID: 30390439]
MGC-803	IC₅₀	26.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 26560049]
MGC-803	IC₅₀	8.82 μM Compound: Gefitinib	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MGC-803	IC₅₀	26.19 μM Compound: Gef	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
MGC-803	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MIA PaCa-2	IC₅₀	45.8 μM Compound: Gefitinib	Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
MIA PaCa-2	ED₅₀	0.51 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MKN-45	IC₅₀	12.29 μM Compound: Gefitinib	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
MOLT-4	IC₅₀	15.02 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay	[PMID: 18313807]
MOLT-4	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
MOLT-4	ED₅₀	>1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
NCI-H1299	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
NCI-H1299	IC₅₀	6.56 μM Compound: Cpd G	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34038131]
NCI-H1299	IC₅₀	4.05 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
NCI-H1299	IC₅₀	40 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35696863]
NCI-H1299	IC₅₀	12.86 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
NCI-H1299	IC₅₀	16.64 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
NCI-H1650	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human H1650 cells by CCK8 assay Antiproliferative activity against human H1650 cells by CCK8 assay	[PMID: 34922028]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H1975	IC₅₀	>33 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
NCI-H1975	IC₅₀	8.26 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 20151670]
NCI-H1975	IC₅₀	9.02 μM Compound: Gfb	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay	[PMID: 22339342]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H1975	IC₅₀	6.917 μM Compound: gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
NCI-H1975	IC₅₀	8.589 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 23792318]
NCI-H1975	IC₅₀	3.3 μM Compound: 1	Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	3.3 μM Compound: 1	Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	13613 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay	[PMID: 24053674]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24411123]
NCI-H1975	IC₅₀	6.917 μM Compound: Iressa	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24607591]
NCI-H1975	IC₅₀	10.48 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
NCI-H1975	IC₅₀	14707 nM Compound: Gefitinib	Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay	[PMID: 25937236]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 26451770]
NCI-H1975	IC₅₀	26.9 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
NCI-H1975	IC₅₀	1.23 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
NCI-H1975	IC₅₀	14.38 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay	[PMID: 27387355]
NCI-H1975	IC₅₀	>10 μM Compound: Iressa	Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-H1975	IC₅₀	10.89 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 27634676]
NCI-H1975	IC₅₀	15.35 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 28236592]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay	[PMID: 28366268]
NCI-H1975	IC₅₀	13.13 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
NCI-H1975	IC₅₀	4.691 μM Compound: 1; Iressa	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
NCI-H1975	EC₅₀	11 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 28711703]
NCI-H1975	EC₅₀	10.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 29421573]
NCI-H1975	IC₅₀	8.58 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
NCI-H1975	IC₅₀	7184 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
NCI-H1975	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 29576272]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 30471829]
NCI-H1975	IC₅₀	9.1 μM Compound: 1	Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30472599]
NCI-H1975	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
NCI-H1975	IC₅₀	12.7 μM Compound: ZD1839	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
NCI-H1975	CC₅₀	18755 nM Compound: Gefitinib	Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	6.5 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	78.7 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	44.6 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NCI-H1975	IC₅₀	4.81 μM Compound: Gefitinib	Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay	[PMID: 32145644]
NCI-H1975	IC₅₀	17.79 μM Compound: Gefitinib	Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
NCI-H1975	IC₅₀	3102 nM Compound: 10	Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant	[PMID: 32432477]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
NCI-H1975	IC₅₀	10.78 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
NCI-H1975	IC₅₀	9.2 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
NCI-H1975	IC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay	[PMID: 34794818]
NCI-H1975	IC₅₀	13.44 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant assessed as inhibition of cell growth Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant assessed as inhibition of cell growth	[PMID: 35728507]
NCI-H1975	IC₅₀	25.56 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
NCI-H1975	IC₅₀	32.15 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
NCI-H1975	IC₅₀	10.1 μM Compound: Gefitinib	Anticancer activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37952262]
NCI-H1975	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
NCI-H1975	IC₅₀	18.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
NCI-H1975	IC₅₀	11.39 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
NCI-H1975	IC₅₀	13.98 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay	10.1039/C3MD00118K
NCI-H1993	IC₅₀	0.1 μM Compound: Gef	Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H1993	IC₅₀	20 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H226	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H23	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H23	IC₅₀	1.02 μM Compound: Gefitinib	Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
NCI-H292	IC₅₀	0.02 μM Compound: Gef	Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H292	IC₅₀	0.41 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H292	IC₅₀	0.12 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H292	IC₅₀	0.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	0.071 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	0.075 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	22 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
NCI-H3255	IC₅₀	40 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells expressing EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells expressing EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 35728507]
NCI-H3255	IC₅₀	0.863 μM Compound: Gefitinib	Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
NCI-H3255	IC₅₀	11 nM Compound: 1	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37934858]
NCI-H3255	IC₅₀	0.007 μM Compound: 1	Antiproliferative activity against human NCI-H3255 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H3255 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
NCI-H358	IC₅₀	14.66 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
NCI-H358	IC₅₀	5.68 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
NCI-H441	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H441 cells harboring K-ras G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H441 cells harboring K-ras G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H460	IC₅₀	5.59 μM Compound: Iressa	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 22727449]
NCI-H460	IC₅₀	7.6 μM Compound: Cefitinib	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability	[PMID: 25105722]
NCI-H460	IC₅₀	21 μM Compound: Gefitinib	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H460	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human H460 cells by CCK8 assay Antiproliferative activity against human H460 cells by CCK8 assay	[PMID: 34922028]
NCI-H522	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H661	IC₅₀	31.06 μM Compound: Gefitinib	Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
NCI-N87	IC₅₀	1 μM Compound: Iressa	Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib	Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NIH3T3	IC₅₀	14.4 nM Compound: gefitinib	Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells	[PMID: 16480284]
NIH3T3	IC₅₀	0.54 μM Compound: Iressa	Growth inhibition of mouse NIH/3T3 cells expressing erB2 gene Growth inhibition of mouse NIH/3T3 cells expressing erB2 gene	[PMID: 19665377]
Non-small cell lung cancer cell line	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Non-small cell lung cancer cells	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-3	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-4	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-8	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PANC-1	IC₅₀	69.32 μM Compound: Gefitinib	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 20304537]
PANC-1	IC₅₀	40.42 μM Compound: Gefitinib	Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
Panel breast (Carcinoma cell lines)	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel breast cells	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel CNS (Carcinoma cell lines)	GI₅₀	8.14 μM Compound: Gefitinib	Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel colon (Carcinoma cell lines)	GI₅₀	7.02 μM Compound: Gefitinib	Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel colon cells	GI₅₀	7.02 μM Compound: Gefitinib	Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel leukemia (Carcinoma cell lines)	GI₅₀	3.54 μM Compound: Gefitinib	Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel leukemia cells	GI₅₀	3.54 μM Compound: Gefitinib	Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel melanoma (Carcinoma cell lines)	GI₅₀	5.28 μM Compound: Gefitinib	Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel melanoma cells	GI₅₀	5.28 μM Compound: Gefitinib	Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	3.24 μM Compound: Gefitinib	Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	3.24 μM Compound: Gefitinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
Panel NCI-60 cells	GI₅₀	3.24 μM Compound: Gefitinib	Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 cells	GI₅₀	3.24 μM Compound: Gefitinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
Panel ovarian (Carcinoma cell lines)	GI₅₀	6.63 μM Compound: Gefitinib	Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel ovarian cells	GI₅₀	6.63 μM Compound: Gefitinib	Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel prostate (Carcinoma cell lines)	GI₅₀	1.65 μM Compound: Gefitinib	Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel prostate cells	GI₅₀	1.65 μM Compound: Gefitinib	Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel renal (Carcinoma cell lines)	GI₅₀	2.67 μM Compound: Gefitinib	Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel renal cells	GI₅₀	2.67 μM Compound: Gefitinib	Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	IC₅₀	15.1 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human PC3 cells after 96 hrs by MTT assay Cytotoxicity against human PC3 cells after 96 hrs by MTT assay	[PMID: 18313807]
PC-3	IC₅₀	22.86 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PC-3	IC₅₀	7.4 μM Compound: ZD1839, Iressa	Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
PC-3	GI₅₀	0.8 μM Compound: Gefitinib	Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	IC₅₀	7.99 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
PC-3	IC₅₀	5.3 μM Compound: Gefitinib	Growth inhibition of human PC3 cells after 5 days by SRB assay Growth inhibition of human PC3 cells after 5 days by SRB assay	[PMID: 32484346]
PC-3	IC₅₀	8.92 μM Compound: Gefitinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
PC-3	IC₅₀	1.37 μM Compound: Gefitinib	Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of BI-3406 by MTT assay Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of BI-3406 by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	9.64 μM Compound: Gefitinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	2.8 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
PC-3	IC₅₀	7.4 μM Compound: Iressa, Gefitinib, ZD1839	Antiproliferative activity against human PC3 cells at 10 uM by MTS assay Antiproliferative activity against human PC3 cells at 10 uM by MTS assay	10.1039/C0MD00183J
PC-9	IC₅₀	0.023 μM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
PC-9	IC₅₀	17 nM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
PC-9	EC₅₀	0.017 μM Compound: Iressa	Antiproliferative activity against EGFR-deficient human PC9 cells Antiproliferative activity against EGFR-deficient human PC9 cells	[PMID: 21208802]
PC-9	EC₅₀	7 μM Compound: Iressa	Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant	[PMID: 21208802]
PC-9	IC₅₀	0.014 μM Compound: Gefitinib	Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
PC-9	IC₅₀	0.0087 μM Compound: 1	Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
PC-9	IC₅₀	6.2 nM Compound: Gefitinib	Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells	[PMID: 26313252]
PC-9	IC₅₀	0.063 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
PC-9	IC₅₀	>10000 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring C797S/T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring C797S/T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	14684 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	16.38 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	6.1 nM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
PC-9	IC₅₀	0.017 μM Compound: Gefitinib	Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay	[PMID: 32145644]
PC-9	IC₅₀	31.32 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 32739648]
PC-9	IC₅₀	0.463 μM Compound: 1	Antiproliferative activity against human PC-9 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human PC-9 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
PLC-PRF-5	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
RXF 393	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf21	IC₅₀	12 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	151 nM Compound: Gefitinib	Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	460 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
SF-295	GI₅₀	2 μM Compound: Gefitinib	Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf9	IC₅₀	0.4 μM Compound: Gefitinib (ZD1839)	TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells	[PMID: 15155841]
Sf9	IC₅₀	0.033 μM Compound: Iressa	Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry	[PMID: 20056425]
Sf9	IC₅₀	0.033 μM Compound: Iressa	Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay	[PMID: 20304535]
Sf9	IC₅₀	0.02 μM Compound: Gefitinib, Iressa	Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis	[PMID: 22119130]
Sf9	IC₅₀	15 nM Compound: Gefitinib	Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	33 nM Compound: Gefitinib	Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	<0.001 μM Compound: gefitinib	Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	<0.001 μM Compound: gefitinib	Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	0.1 μM Compound: gefitinib	Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	>1 μM Compound: 1	Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.003 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.343 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.476 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	15.5 nM Compound: Gefitinib	Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
Sf9	IC₅₀	823.3 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
Sf9	IC₅₀	0.39 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	3.17 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
Sf9	IC₅₀	4.99 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
SGC-7901	IC₅₀	10.26 μM Compound: Iressa	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22727449]
SGC-7901	IC₅₀	29.01 μM Compound: Gefitinib	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
SH-SY5Y	IC₅₀	18.21 μM Compound: 2	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23871909]
SH-SY5Y	IC₅₀	18.21 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 28711702]
SH-SY5Y	IC₅₀	18.216 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
SK-BR-3	IC₅₀	0.174 μg/mL Compound: 1 iressa	Inhibition of SKBR-3 cell proliferation Inhibition of SKBR-3 cell proliferation	[PMID: 12270171]
SK-BR-3	IC₅₀	4.92 μM Compound: Gefitinib	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay	[PMID: 27132165]
SK-BR-3	IC₅₀	2518 nM Compound: Gefitinib	Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
SK-BR-3	IC₅₀	5.36 μM Compound: Gefitinib	Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
SK-HEP1	IC₅₀	10.1 μM Compound: Gefitinib	Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay	[PMID: 29407971]
SK-MEL-28	IC₅₀	>20 μM Compound: 3	Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay	[PMID: 24588073]
SK-MEL-28	GI₅₀	0.32 μM Compound: Gefitinib	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SK-OV-3	IC₅₀	24.5 μM Compound: Gefitinib	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
SMMC-7721	IC₅₀	33.12 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20304537]
SMMC-7721	IC₅₀	4.16 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
SMMC-7721	IC₅₀	9.2 μM Compound: Gefitinib	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
SNB-75	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SNU-638	IC₅₀	7.56 μM Compound: Gefitinib	Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 29407971]
SR	GI₅₀	3.16 μM Compound: Gefitinib	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
SW480	IC₅₀	12.5 μM Compound: ZD1839	Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
SW-620	IC₅₀	>5 μg/mL Compound: 1 iressa	Inhibition of SW-620 cell proliferation Inhibition of SW-620 cell proliferation	[PMID: 12270171]
SW-620	IC₅₀	>10 μM Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20151670]
SW-620	IC₅₀	28.2 μM Compound: Gefitinib	Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
T-24	IC₅₀	599 nM Compound: gefitinib	Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells	[PMID: 16480284]
T-24	IC₅₀	14.6 μM Compound: Gef	Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 32827851]
T47D	IC₅₀	3.47 μM Compound: Gefitinib	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
TK-10	GI₅₀	0.1 μM Compound: Gefitinib	Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-251	IC₅₀	10.8 μM Compound: Cefitinib	Cytotoxicity against human U251 cells assessed as reduction in cell viability Cytotoxicity against human U251 cells assessed as reduction in cell viability	[PMID: 25105722]
U-251	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-251	IC₅₀	10.88 μM Compound: Gefitinib	Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay	[PMID: 38739112]
U-87MG ATCC	IC₅₀	8.2 μM Compound: Gefitinib	Antiproliferative activity against human U87 cells after 48 hrs by MTT assay Antiproliferative activity against human U87 cells after 48 hrs by MTT assay	[PMID: 28462838]
U-87MG ATCC	IC₅₀	22.4 μM Compound: 1	Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
U-87MG ATCC	IC₅₀	10.35 μM Compound: Gefitinib	Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay	[PMID: 38739112]
UACC-257	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UACC-62	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UO-31	GI₅₀	1.26 μM Compound: Gefitinib	Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Vero	IC₅₀	>100 μM Compound: Gefitinib	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 28927795]
Vero	IC₅₀	>10 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30655941]
WM 266-4	IC₅₀	17.42 μM Compound: Gefitinib	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]

In Vitro

Gefitinib (0.01-0.1? μM, 72 h) results in increased phosphotyrosine load of the receptor, increased signalling to ERK and stimulation of proliferation and anchorage-independent growth^[2].
Gefitinib (1-2 μM, 72 h) significantly decreases EGFRvIII phosphotyrosine load, EGFRvIII-mediated proliferation and anchorage-independent growth^[2].
Gefitinib (0.62 μM, 24-72 h) inhibits IL-13-induced M2-like polarization of RAW 264.7 cells through the STAT6-dependent signaling pathway^[3].
Gefitinib (0.62 μM, 72 h) inhibits M2-like macrophage-promoted invasion and migration^[3].
Gefitinib (0-10 μM, 72 h) induces apoptosis (induction of BIM protein) in NSCLC Cell Lines (H3255 and HCC827 cells)^[4].
Gefitinib (100 nM, 24 h) suppresses macropinocytosis and increases the cellular uptake of extracellular vesicles( EVs) in HCC827 and A549 cells^[6].
Gefitinib (1.5-60 μM, 48 h) increases inhibition of proliferation in H358^R and A549^R cells (Cisplatin-resistant wtEGFR NSCLC cell lines)^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

NR6wtEGFR, NR6W and NR6M
Concentration:

1, 10, 100 μM
Incubation Time:

5 h
Result:

Inhibited EGFR tyrosine phosphorylations.

Cell Migration Assay ^[3]

Cell Line:

LLCs cell
Concentration:

0.62 μM
Incubation Time:

72 h
Result:

Abrogated M2-like macrophage promoted invasion and migration of LLCs.

In Vivo

Gefitinib (Oral administration, 75 mg/kg/d, 21 days) inhibits the M2-like polarization of macrophages in LLC mice metastasis model^[3].
Gefitinib (Oral administration, 75 mg/kg for the initial week, daily for 5 consecutive days per week) eliminates phosphorylation of HER2 and HER3 and signaling through MAPK and Akt in lobular hyperplasias and carcinomas, increases MAPK activity and cytokine production in splenocytes and lymph nodes^[5]. Gefitinib (Oral gavage, 150 mg/kg, daily) enhances the anti-tumor effect of Cisplatin in H358^R xenograft^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LLC mice metastasis model^[3]
Dosage:

75 mg/kg/d, for 21 days.
Administration:

Oral administration
Result:

Reduced the number of lung metastasis nodules, down-regulated the expression of M2 marker genes and the percentages CD206⁺ and CD68⁺ macrophages in tumor tissues.

Animal Model:

BALB-NeuT transgenic mouse model^[5]
Dosage:

75 mg/kg for the initial week, and increased by 15 mg/kg every other week, daily for 5 consecutive days per week, followed by 2 days without treatment and repeated for 8–9 weeks.
Administration:

Oral administration
Result:

Reduced tumor multiplicity from 9.6 to 0.58 (83%), and reduced the number and size of lobules and lobular nodules in treated mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 184475-35-2
Appearance Solid
Molecular Weight 446.90
Formula C₂₂H₂₄ClFN₄O₃
Color White to off-white
SMILES

ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F
Synonyms

ZD1839
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (206)

All WBCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness. [Abstract]

2019 Dec 13;4:60. PMID: 31871777
Cancer Cell

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. [Abstract]

2025 Jul 25:S1535-6108(25)00310-1. PMID: 40780213
Cancer Cell

Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. [Abstract]

2018 Jun 11;33(6):1061-1077.e6. PMID: 29894692

Gefitinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. [Abstract]

WT mice are either treated with vehicle or Gefitinib (100 mg/kg/day) starting one day prior to DEN injection (100 mg/kg). Livers are collected at 3 and 48 hr after DEN injection and subjected to IB analyses with the indicated antibodies.
Cell

ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. [Abstract]

2026 May 28;189(11):3413-3431.e19. PMID: 42054992
Mol Cancer

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer. [Abstract]

2025 Apr 23;24(1):122. PMID: 40264166
Mol Cancer

A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression. [Abstract]

2024 Jul 9;23(1):141. PMID: 38982480
Adv Mater

Highly Specific Cytokine Receptor-Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer. [Abstract]

2025 May 22:e2504050. PMID: 40401615
Nat Biomed Eng

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. [Abstract]

2018 Aug;2(8):578-588. PMID: 31015631
Cell Res

In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. [Abstract]

2021 Jun;31(6):631-648. PMID: 33782530
Cell Res

Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. [Abstract]

2020 Oct;30(10):833-853. PMID: 32499560

Gefitinib purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]

Western blot showing EGFR phosphorylation (Y1173 and Y1068) as a biomarker of EGFR activation following treatment with erlotinib or gefitinib (0.2-1 μM) for 24 hours in sphere culture at the indicated concentrations.

Gefitinib purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]

Immunofluorescence showing phospho-EGFR (Y1173) expression in GSCs in 3D tetracultures following treatment with 1μM of erlotinib or gefitinib for 24 hours. Scale bar, 25μm.
Mol Cell

Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. [Abstract]

2025 Mar 21:S1097-2765(25)00194-7. PMID: 40139189
Cancer Res

Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer. [Abstract]

2023 Jul 5;83(13):2187-2207. PMID: 37061993
Nat Commun

An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression. [Abstract]

2026 Jan 21;17(1):1902. PMID: 41565660
Nat Commun

PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma. [Abstract]

2025 Feb 1;16(1):1237. PMID: 39890801
Nat Commun

Synthetic vectors for activating the driving axis of ferroptosis. [Abstract]

2024 Sep 10;15(1):7923. PMID: 39256387
Nat Commun

Therapeutic potential of the secreted Kazal-type serine protease inhibitor SPINK4 in colitis. [Abstract]

2024 Jul 12;15(1):5874. PMID: 38997284
Nat Commun

CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling. [Abstract]

2023 Jun 15;14(1):3560. PMID: 37322019
Nat Commun

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]

2023 Apr 24;14(1):2342. PMID: 37095176
Nat Commun

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. [Abstract]

2019 Apr 18;10(1):1812 PMID: 31000705
Sci Transl Med

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. [Abstract]

2021 Sep;13(609):eabb3738. PMID: 34516823
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Adv Sci (Weinh)

Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. [Abstract]

2026 Feb 3:e16660. PMID: 41632021
Adv Sci (Weinh)

Real-Time Visualization of Isoform-Specific RAF-KRAS Interactions in Living Cells Using FRET-BRET Hybrid Biosensors. [Abstract]

2026 Feb 12:e15654. PMID: 41674298
Theranostics

Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway. [Abstract]

2018 Jul 30;8(15):4262-4278. PMID: 30128052

Gefitinib purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefitinib at 2.5 µM, SU 11248 at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. [Abstract]

2019 Mar 15;38(1):129. PMID: 30876460
J Exp Clin Cancer Res

GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. [Abstract]

2018 Nov 29;37(1):295. PMID: 30497501
Redox Biol

PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis. [Abstract]

2026 Apr:91:104093. PMID: 41723906
J Control Release

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]

2024 Dec:376:829-841. PMID: 39491626
EBioMedicine

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes. [Abstract]

2023 Jan:87:104410. PMID: 36525723
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma. [Abstract]

2023 Sep 19;4(9):101177. PMID: 37652019
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
J Exp Med

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. [Abstract]

2022 Jan 3;219(1):e20210789. PMID: 34825915
Pharmacol Res

Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. [Abstract]

2019 Jun:144:79-89. PMID: 30974169
Cancer Lett

Identification and characterization of Bufalin as a novel EGFR degrader. [Abstract]

2025 Apr 10:217715. PMID: 40220852
Nat Struct Mol Biol

RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growth. [Abstract]

2024 May 20. PMID: 38769389
Int J Biol Sci

MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer. [Abstract]

2021 Apr 12;17(7):1671-1681. PMID: 33994852
Adv Healthc Mater

Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib-Resistant Non-Small Cell Lung Cancer. [Abstract]

2024 Nov 25:e2402884. PMID: 39586988
Cell Death Dis

PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target. [Abstract]

2023 Oct 11;14(10):671. PMID: 37821451
Cell Death Dis

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. [Abstract]

2020 Nov 11;11(11):969. PMID: 33177491
Cell Death Dis

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. [Abstract]

2019 May 1;10(5):361. PMID: 31043587
Cell Death Dis

EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. [Abstract]

2018 Feb 15;9(3):269. PMID: 29449645

Gefitinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]

WB is used to detect the effect of EGF treatment for 4 h on the expression of YAP with the inhibitors of EGFR or its downsream members, including Gefitinib, LY294002, Wortmannin, GSK2334470, BX-795, MK-2206, GSK1120212, and U0126 in the Si RhoA transfected HepG2 and SMMC7721 cells for 48 h in HepG2 and SMMC7721 cells.
Genes Dis

2025 Nov 25.
J Pharm Anal

Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway. [Abstract]

2024 Aug;14(8):100984. PMID: 39258171
Dev Cell

Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages. [Abstract]

2025 May 15:S1534-5807(25)00287-4. PMID: 40403724
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Phytomedicine

Paeoniflorin alleviates anxiety-like behaviors in sleep-deprived male mice by suppressing inflammation of the paraventricular nucleus of the hypothalamus. [Abstract]

2026 Jun:155:158111. PMID: 41931995
Phytomedicine

Yifei Sanjie pill combined with gefitinib reduces the progression of EGFR-TKIs-resistant non-small cell lung cancer via YAP/ANKRD1 axis. [Abstract]

2026 Jun:155:158003. PMID: 41865688
Phytomedicine

Tougu Xiaotong capsules inhibit lung cancer and gefitinib-resistant cells by blocking ERBB2/PI3K-AKT-mTOR signaling and triggering ferroptosis. [Abstract]

2025 Dec 26:150:157741. PMID: 41477979
Phytomedicine

Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. [Abstract]

2025 Oct 8:148:157387. PMID: 41106095
Phytomedicine

Flemiphilippinin A induces paraptosis in lung cancer cells via c-Myc-driven endoplasmic reticulum stress and CHOP-mediated mitochondrial dysfunction. [Abstract]

2025 Oct:146:157098. PMID: 40716126
Phytomedicine

Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways. [Abstract]

2023 Jul 25:116:154884. PMID: 37209605
NPJ Precis Oncol

High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. [Abstract]

2026 Apr 8;10(1):211. PMID: 41951768
Haematologica

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. [Abstract]

2020 Jan;105(1):124-135. PMID: 30948489
Cell Syst

Large-scale control over collective cell migration using light-activated epidermal growth factor receptors. [Abstract]

2025 Mar 19;16(3):101203. PMID: 40037348
Biomed Pharmacother

Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. [Abstract]

2019 Sep:117:109185. PMID: 31387179
Oncogene

Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability. [Abstract]

2026 Jun 15. PMID: 42298179
Oncogene

SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer. [Abstract]

2021 Jul;40(30):4884-4893. PMID: 34163029
Oncogene

Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. [Abstract]

2021 Apr;40(14):2596-2609. PMID: 33750895
Oncogene

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. [Abstract]

2018 Aug;37(31):4300-4312. PMID: 29717264

Gefitinib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Aug;37(31):4300-4312. [Abstract]

Western blot analysis of E-cadherin and vimentin in HCC827 xenograft tumors treated with Gefitinib daily for 6-8 weeks until tumors regrown (resistant) or saline for 1 week (sensitive) (left panel).
J Anal Test

2025 Sep 25.
Cell Death Discov

Targeting the up-regulated CNOT3 reverses therapeutic resistance and metastatic progression of EGFR-mutant non-small cell lung cancer. [Abstract]

2023 Nov 2;9(1):406. PMID: 37919290
Cell Rep

Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. [Abstract]

2019 Jul 9;28(2):512-525.e6. PMID: 31291585
Arch Toxicol

Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters. [Abstract]

2018 Jun;92(6):2027-2042. PMID: 29725709
Clin Transl Med

Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. [Abstract]

2026 Mar;16(3):e70638. PMID: 41804750
J Med Chem

Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4. [Abstract]

2025 Mar 13;68(5):5275-5291. PMID: 39968846
Anal Chem

Quantum Well-Enhanced Plasmonic Substrate to Enhance Spontaneously Blinking Fluorescence for Single-Molecule Localization Microscopy. [Abstract]

2026 Mar 24;98(11):7999-8009. PMID: 41805316
Fundam Res

Gefitinib facilitates PINK1/Parkin-mediated mitophagy by enhancing mitochondrial recruitment of OPTN. [Abstract]

2022 Mar 3;2(5):807-816. PMID: 38933121
Cell Mol Life Sci

IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. [Abstract]

2019 May;76(10):2015-2030. PMID: 30725116
Cancer Cell Int

Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation. [Abstract]

2021 Dec 7;21(1):655. PMID: 34876150
Food Biosci

2025 Jul.
J Invest Dermatol

Blue light irradiation induces skin barrier damage through EGFR/ERK/c-Jun signaling pathway. [Abstract]

2026 Feb 23:S0022-202X(26)00102-8. PMID: 41740835
J Invest Dermatol

LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways. [Abstract]

2022 Feb;142(2):303-313.e9. PMID: 34358528
Biochem Pharmacol

Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. [Abstract]

2026 Jan;243(Pt 2):117562. PMID: 41314435
Biochem Pharmacol

Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma. [Abstract]

2025 Jun 6:239:117032. PMID: 40482839
Neurobiol Dis

ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. [Abstract]

2020 Aug;142:104961. PMID: 32531343
Breast Cancer Res

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. [Abstract]

2017 Aug 4;19(1):90. PMID: 28778177

Gefitinib purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]

The effect of Gefitinib-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates are exposed for 24 h to Gefitinib (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720.
Mol Cancer Ther

AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. [Abstract]

2023 Sep 5;22(9):1013-1027. PMID: 37302522
J Ethnopharmacol

Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway. [Abstract]

2023 Oct 5:314:116566. PMID: 37169317
Chem Biol Interact

E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. [Abstract]

2022 Feb 25:354:109798. PMID: 34998818
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
Respir Res

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. [Abstract]

2024 May 20;25(1):215. PMID: 38764025
Int J Mol Sci

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 as a Biomarker for Predicting Response to Erlotinib and Gefitinib in Lung Adenocarcinoma: An Integrative Analysis of Transcriptomic Data of PC-9 and Drug-Resistant PC-9 Cell Lines. [Abstract]

2026 Mar 28;27(7):3092. PMID: 41977278
Int J Oncol

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. [Abstract]

2022 Nov;61(5):139. PMID: 36169178
Int J Mol Sci

Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration. [Abstract]

2022 Feb 28;23(5):2664. PMID: 35269804
Int J Mol Sci

miR-196a Upregulation Contributes to Gefitinib Resistance through Inhibiting GLTP Expression. [Abstract]

2022 Feb 4;23(3):1785. PMID: 35163707
Int J Mol Sci

Disabled 1 Is Part of a Signaling Pathway Activated by Epidermal Growth Factor Receptor. [Abstract]

2021 Feb 9;22(4):1745. PMID: 33572344
Int J Mol Sci

Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies. [Abstract]

2018 Oct 15;19(10). pii: E3165. PMID: 30326566
Cell Oncol (Dordr)

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers. [Abstract]

2025 Jul 10. PMID: 40637801
Pharmaceuticals (Basel)

β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy. [Abstract]

2024 May 14;17(5):626. PMID: 38794196
Pharmaceuticals (Basel)

Antiproliferative Activity of a New Quinazolin-4(3 H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer. [Abstract]

2022 Jun 2;15(6):698. PMID: 35745617
Cell Oncol (Dordr)

Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). [Abstract]

2021 Feb;44(1):109-133. PMID: 32894437
Eur J Pharm Sci

Preclinical validation of tetrahydroquinoline derivatives as EGFR inhibitor inducing glioblastoma cell death. [Abstract]

2026 Mar 14:107503. PMID: 41839309
Int Immunopharmacol

ELK3-SERPINE1-PCBP2 axis promotes gefitinib resistance in lung cancer by inhibiting ferroptosis. [Abstract]

2025 Dec 10:169:115963. PMID: 41380194
Int Immunopharmacol

CD9 downregulation activates EGFR/ERK/WAVE2 pathway to remodel F-actin and promote proliferation and migration of cholesteatoma epithelial cells. [Abstract]

2025 Aug 25:164:115401. PMID: 40858050
Bioorg Chem

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation. [Abstract]

2025 Aug 9:164:108864. PMID: 40815992
Bioorg Chem

A novel Quinazoline derivative exerts anti-tumor effects in non-small cell lung cancer through Wnt/β-catenin pathway inhibition. [Abstract]

2025 Apr 15:160:108481. PMID: 40253763
Eur J Pharmacol

Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors. [Abstract]

2023 Dec 5:960:176114. PMID: 37863412
Eur J Pharmacol

Mechanisms of gefitinib-induced QT prolongation. [Abstract]

2021 Nov 5:910:174441. PMID: 34474028
Mol Cancer Res

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells. [Abstract]

2019 Feb;17(2):499-507. PMID: 30463991
Front Endocrinol

Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy. [Abstract]

2018 Mar 22:9:120. PMID: 29623068
Molecules

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]

2018 Mar 23;23(4). pii: E736. PMID: 29570606
Cell Rep Methods

Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]

2026 Jun 15;6(6):101339. PMID: 42134319
J Mol Biol

A Fluorescent Probe Targeting EGFR for the Stratification of Prostate Cancer Cells. [Abstract]

2025 Jun 2:169261. PMID: 40466906
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cell Rep Methods

A hybrid deep forest-based method for predicting synergistic drug combinations. [Abstract]

2023 Feb 21;3(2):100411. PMID: 36936075
Front Microbiol

EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection. [Abstract]

2022 Jun 30;13:894356. PMID: 35847084
Cancers (Basel)

Triptolide Triggers Protective Autophagy via ROS Induction in NSCLC: Therapeutic Synergy with Autophagy Inhibition. [Abstract]

2026 Mar 11;18(6):902. PMID: 41899507
Lung Cancer

Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC. [Abstract]

2023 Jul:181:107258. PMID: 37245409
Biochim Biophys Acta Mol Basis Dis

FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer. [Abstract]

2023 Apr;1869(4):166665. PMID: 36781088
J Cell Mol Med

CRKL is a critical target of Hh-GLI2 pathway in lung adenocarcinoma. [Abstract]

2021 Jul;25(13):6280-6288. PMID: 34076957
J Cell Mol Med

RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. [Abstract]

2021 Mar;25(5):2418-2425. PMID: 33491264
Drug Dev Res

Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer. [Abstract]

2021 May;82(3):422-429. PMID: 33231319
J Cell Mol Med

Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer. [Abstract]

2020 May;24(10):5578-5592. PMID: 32248643
J Funct Foods

2025 Apr.
Adv Ther

2024 Jul 18.
J Funct Foods

April 2022, 104997.
AAPS PharmSciTech

Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties. [Abstract]

2022 Jan 4;23(1):48. PMID: 34984564
Oncol Rep

Inhibition of primary ciliogenesis enhances efficacy of EGFR‑TKIs against non‑small cell lung cancer cells. [Abstract]

2026 Feb;55(2):30. PMID: 41347810
Sci Rep

Rosmarinic acid potentiates gefitinib in lung adenocarcinoma by modulating interactions between cancer cells and cancer-associated fibroblasts. [Abstract]

2025 Jul 6;15(1):24100. PMID: 40619518
Sci Rep

Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. [Abstract]

2024 Mar 27;14(1):7303. PMID: 38538642
Oncol Rep

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. [Abstract]

2023 May;49(5):84. PMID: 36896765
Aquaculture

2021, 539: 736614.
J Biol Chem

SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. [Abstract]

2022 Nov;298(11):102511. PMID: 36259516
Oncol Rep

M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF. [Abstract]

2020 Aug;44(2):698-710. PMID: 32627036
Fish Shellfish Immunol

Molecular characterization and function of EGFR during viral infectionprocess in Mandarin fishSiniperca chuatsi. [Abstract]

2020 Jul;102:211-217. PMID: 32298770
Oncol Rep

Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. [Abstract]

2018 Oct;40(4):2242-2250. PMID: 30066906

Gefitinib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Oct;40(4):2242-2250. [Abstract]

Effects of Gefitinib(G) and SC 58635 (Cel) on ABCB1 (MDR1), FOXM1 and Bcl 2 protein levels in PC3/DR and DU145/DR cell lines. The effects of Gefitinib, SC 58635 and their combination on ABCB1 (MDR1), FOXM1 and Bcl 2 expression in the PC3/DR and DU145/DR cell lines are determined by a western blot assay.
Cancer Res Treat

MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis. [Abstract]

2023 Jul;55(3):778-803. PMID: 36701842
Cell Signal

Effects of heterologous kinase domains on growth factor receptor specificity. [Abstract]

2024 Oct:122:111307. PMID: 39048037
Mol Med Rep

ISX promotes tumor migration and invasion in lung cancer by upregulating COL1A1 in vitro. [Abstract]

2026 Feb;33(2):77. PMID: 41480691
Transl Lung Cancer Res

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]

2025 Jun 30;14(6):2159-2179. PMID: 40673102
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
Viruses

The Role of Epidermal Growth Factor Receptor Signaling Pathway during Bovine Herpesvirus 1 Productive Infection in Cell Culture. [Abstract]

2020 Aug 24;12(9):927. PMID: 32846937
Exp Cell Res

PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. [Abstract]

2017 Dec 15;361(2):246-256. PMID: 29080795

Gefitinib purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2017 Dec 15;361(2):246-256. [Abstract]

Western blot analysis for p21, p-p21, Cyclin D1. Bcl-2, Caspase 3, Cleaved Caspase 3, Caspase 9, Cleaved Caspase 9 and Bax in HCC827-GR and PC-9-GR cells treated with control, Efatutazone alone, Gefitinib alone, or Efatutazone combined with gefitinib for 48 h.
Mol Med Rep

Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. [Abstract]

2017 Sep;16(3):3475-3481. PMID: 28713965

Gefitinib purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2017 Sep;16(3):3475-3481. [Abstract]

Cyclin B1 and Cdk1 protein expression levels are significantly downregulated in NCI-H1975 cells treated with the combination of DHA (5 µM) and Gefitinib (10 µM).
Toxicol Appl Pharmacol

MiR-29a/DNMT3A axis participates in Dihydroartemisinin's suppression on lung adenocarcinoma: Implications for overcoming acquired resistance to EGFR-TKIs. [Abstract]

2026 Mar 4:511:117777. PMID: 41791429
Food Nutr Res

TLR2/4-mediated NF-κB pathway combined with the histone modification regulates β-defensins and interleukins expression by sodium phenyl butyrate in porcine intestinal epithelial cells. [Abstract]

2018 Dec 6:62. PMID: 30574051
Endocrinology

Casein kinase 1α regulates testosterone synthesis and testis development in adult mice. [Abstract]

2023 Mar 13;164(5):bqad042. PMID: 36929849
Front Oncol

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. [Abstract]

2022 Sep 8:12:944537. PMID: 36158676
Front Oncol

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib. [Abstract]

2020 Dec 23:10:597434. PMID: 33425751
Front Oncol

Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling. [Abstract]

2020 Oct 5;10:542007. PMID: 33123465
Int J Med Sci

Nephronectin promotes cardiac repair post myocardial infarction via activating EGFR/JAK2/STAT3 pathway. [Abstract]

2022 May 13;19(5):878-892. PMID: 35693734
Kaohsiung J Med Sci

Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. [Abstract]

2023 Jul;39(7):699-709. PMID: 37057810

Gefitinib purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Jul;39(7):699-709. [Abstract]

Gefitinib (0-20 μM; 24 h) significantly inhibits the viability of A549 cells.
Ren Fail

Dihydromyricetin protects against cisplatin-induced renal injury and mitochondria-mediated apoptosis via the EGFR/HSP27/STAT3 signaling pathway. [Abstract]

2025 Dec;47(1):2490202. PMID: 40230054
Breast Cancer Res Treat

IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development. [Abstract]

2025 Jun;211(2):467-478. PMID: 40055251
FEBS Lett

MEK/ERK MAP kinase limits poly I:C-induced antiviral gene expression in RAW264.7 macrophages by reducing interferon-beta expression. [Abstract]

2021 Nov;595(21):2665-2674. PMID: 34591979
Mol Pharmacol

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. [Abstract]

2019 Dec;96(6):862-870. PMID: 31554698
Genes (Basel)

The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids. [Abstract]

2024 Dec 19;15(12):1624. PMID: 39766891
J Chromatogr B Analyt Technol Biomed Life Sci

Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]

2024 Apr 15:1237:124100. PMID: 38547701
BMC Pulm Med

The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC). [Abstract]

2023 May 11;23(1):162. PMID: 37165402
Infect Immun

Bartonella henselae Persistence within Mesenchymal Stromal Cells Enhances Endothelial Cell Activation and Infectibility That Amplifies the Angiogenic Process. [Abstract]

2021 Jul 15;89(8):e0014121. PMID: 34031126
J Cancer Res Clin Oncol

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. [Abstract]

2020 Jul;146(7):1737-1749. PMID: 32342201
Mol Pain

The upregulation of EGFR in the dorsal root ganglion contributes to chronic compression of dorsal root ganglions-induced neuropathic pain in rats. [Abstract]

2019 Jan-Dec:15:1744806919857297. PMID: 31215332
J Sep Sci

Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. [Abstract]

2017 Oct;40(19):3782-3791. PMID: 28749011
Exp Eye Res

SN promote retinal pathological neovascularization through activation of EGFR, IR and IGF-1R. [Abstract]

2024 Nov 14:110158. PMID: 39549871
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Cancer Manag Res

Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway. [Abstract]

2024 May 28:16:507-525. PMID: 38827785
Biomed Res Int

B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns. [Abstract]

2020 Dec 24:2020:8824805. PMID: 33426073
Biochem Biophys Res Commun

2026 Feb 12:800:153165. PMID: 41548485
Oncol Lett

Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation. [Abstract]

2024 Jul 30;28(4):466. PMID: 39119229
Oncol Lett

Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways. [Abstract]

2022 Aug 24;24(4):356. PMID: 36168315
Anticancer Res

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers. [Abstract]

2020 Apr;40(4):1855-1866. PMID: 32234873
Biomed Chromatogr

Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. [Abstract]

2016 Jul;30(7):1150-4. PMID: 26525154
Biochem Genet

GSDME Deficiency Suppresses ER Stress-Induced Autophagic Cell Death via mTOR/S6K1 Activation in Hepatobiliary Carcinomas. [Abstract]

2025 May 23. PMID: 40407851
Am J Transl Res

Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. [Abstract]

2019 Jun 15;11(6):3543-3554. PMID: 31312365
Curr Med Sci

Huaier Aqueous Extract Combined with Gefitinib Promotes ACSL4-Dependent Ferroptosis and Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer. [Abstract]

2026 Feb;46(1):197-211. PMID: 41557244
Drug Discov Ther

Development of a simple high-performance liquid chromatography-ultraviolet detection method for selpercatinib determination in human plasma. [Abstract]

2025 Jan 14;18(6):387-390. PMID: 39647867
Biol Methods Protoc

Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]

2025 Feb 13;10(1):bpaf012. PMID: 40060949
Chem Pharm Bull (Tokyo)

Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells. [Abstract]

2017 Aug 1;65(8):768-775. PMID: 28539531

Gefitinib purchased from MedChemExpress. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775. [Abstract]

Changes in Bcl-2 protein expression in MCF-7 cells after treatment with 2CdA, BMS-354825 or Gefitinib alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.
bioRxiv

2026 Jun 22.
bioRxiv

Preservation of Human Colonic Stem Cells Requires an ERK Dynamics Checkpoint Mediated by AKT. [Abstract]

2026 Apr 11:2026.04.02.715982. PMID: 41959484
bioRxiv

2026 Mar 12.
Patent

US20260034087A1.
Indiana University

2026.
J Physiol Investig

Pectolinarigenin Induces Mitochondrion-dependent Apoptosis, Causes G2/M Arrest, and Inhibits Migration and Invasion in Rheumatoid Arthritis-Fibroblast-like Synoviocytes. [Abstract]

2026 Jan 1;69(1):42-56. PMID: 41606826
bioRxiv

2025 Dec 5.
bioRxiv

A non-canonical AKT1-TERT pathway coordinates autophagy and ERphagy. [Abstract]

2025 Nov 26:2025.11.24.690135. PMID: 41383764
University of Otago

2025 Oct 7.
University of New York

2025.
Res Sq

2025 Jul 20.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. [Abstract]

2025 Jun 7:2025.06.04.657911. PMID: 40502048
bioRxiv

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. [Abstract]

2025 Jun 24:2025.06.18.660406. PMID: 40667242
Princeton University

2025.
Indiana University

2025.
bioRxiv

2025 May 10.
Eur J Pharm Med Res

2024, 11(7), 136-153.
bioRxiv

2024 October 29.
bioRxiv

2024 October 24.
bioRxiv

Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KrasG12D oncogene-expressing tumor cells. [Abstract]

2024 Jul 26:2024.07.26.605291. PMID: 41030963
bioRxiv

2024 June 12.
bioRxiv

Large-scale control over collective cell migration using light-controlled epidermal growth factor receptors. [Abstract]

2024 May 31:2024.05.30.596676. PMID: 38853934
bioRxiv

2024 Feb 12.
Res Sq

Mycobacterium tuberculosis resides in lysosome-poor monocyte-derived lung cells during chronic infection. [Abstract]

2023 Jun 15:rs.3.rs-3049913. PMID: 37398178
Research Square Preprint

2023 May 4.
Oxid Med Cell Longev

Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. [Abstract]

2023 Jan 31:2023:1367938. PMID: 36760347
Research Square Print

December 9th, 2022.
Research Square Print

October 18th, 2022.
Cell Insight

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity. [Abstract]

2022 Jun 16;1(4):100045. PMID: 37192859
SSRN

31 Aug 2021.
Azhar Int J Pharm Med Sci

2021;1 (1):66-72.
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827
Oncotarget

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model. [Abstract]

2017 Oct 19;8(58):98771-98781. PMID: 29228726
Oncotarget

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. [Abstract]

2016 Oct 25;7(43):69760-69769. PMID: 27626175
Oncotarget

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. [Abstract]

2015 Oct 13;6(31):31313-22. PMID: 26375053

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (223.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2376 mL

11.1882 mL

22.3764 mL

5 mM

0.4475 mL

2.2376 mL

4.4753 mL

10 mM

0.2238 mL

1.1188 mL

2.2376 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (11.19 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: 0.5 mg/mL (1.12 mM); Suspended solution; Need ultrasonic

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 5 mg/mL (11.19 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 3.33 mg/mL (7.45 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (925 KB)
- English - EN (925 KB)
- Français - FR (925 KB)
- Deutsch - DE (925 KB)
- Norwegian - NO (925 KB)
- Español - ES (925 KB)
- Swedish - SV (925 KB)
- Italian - IT (925 KB)
- Portuguese - PT (925 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. [Content Brief]

[2]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [Content Brief]

[3]. Muhammad Tariq, et al. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017 Nov;38(11):1501-1511. [Content Brief]

[4]. Mark S Cragg, et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690. [Content Brief]

[5]. Marie P Piechocki, et al. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer. 2008 Apr 15;122(8):1722-9. [Content Brief]

[6]. Tomoya Takenaka, et al. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. Int J Pharm. 2019 Dec 15;572:118762. [Content Brief]

[7]. Amin Li, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020 Jul;146(7):1737-1749. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2376 mL	11.1882 mL	22.3764 mL	55.9409 mL
	5 mM	0.4475 mL	2.2376 mL	4.4753 mL	11.1882 mL
	10 mM	0.2238 mL	1.1188 mL	2.2376 mL	5.5941 mL
	15 mM	0.1492 mL	0.7459 mL	1.4918 mL	3.7294 mL
	20 mM	0.1119 mL	0.5594 mL	1.1188 mL	2.7970 mL
	25 mM	0.0895 mL	0.4475 mL	0.8951 mL	2.2376 mL
	30 mM	0.0746 mL	0.3729 mL	0.7459 mL	1.8647 mL
	40 mM	0.0559 mL	0.2797 mL	0.5594 mL	1.3985 mL
	50 mM	0.0448 mL	0.2238 mL	0.4475 mL	1.1188 mL
	60 mM	0.0373 mL	0.1865 mL	0.3729 mL	0.9323 mL
	80 mM	0.0280 mL	0.1399 mL	0.2797 mL	0.6993 mL
	100 mM	0.0224 mL	0.1119 mL	0.2238 mL	0.5594 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Gefitinib

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Gefitinib

All EGFR Isoforms

Biological Activity

Chemical Information

Publications (206)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Gefitinib Related Classifications

Cat. No.: HY-50895